10th July, 2018
Cyber Essentials Certification
We are proud to announce that Bowmed Ibisqus now holds the government-recommended Cyber Essentials certificate from the National Cyber Security Centre.
As suppliers of critical injectable medicines to the NHS hospital and private sector, we take our data security very seriously and are committed to safeguarding it against all types of cyber and IT threats.
In fact, demonstrating cyber and IT security controls to our private and NHS clients is a big part of our corporate governance program.
According to NHS Improvement’s Data Security Protection Requirements Guidance, health and care organisations must comply with a set of ten data and cyber security requirements. One of these includes ensuring that any supplier of critical IT systems that could impact on the delivery of care, or process personal identifiable data has the appropriate security certification such as Cyber Essentials.
9th July, 2018
IBI Lorenzini meet FMD challenges head on and in advance of deadline
We are pleased to report that our Italian-based group company IBI Lorenzini has partnered with Tracelink to implement global serialisation solutions ahead of the February 2019 FMD deadline.
The IBI Lorenzini commercial operation brings together traditional pharma and contract manufacturing expertise therefore it was important for the group to find a partner that could provide the specialist knowledge on its global ‘track and trace’ requirements. The flexibility, scalability, speed and efficiency of the Tracelink EU hub have met the IBI group’s stringent requirements.
The Falsified Medicines Directive (FMD) and the US Drug Supply Chain Security Act (DSCSA) legislation have presented the pharmaceutical industry with one of the most challenging undertakings in recent times. Investment in the IBI Lorenzini plant and in the right partnerships has therefore been crucial to a smooth implementation.
With a booming export division in over 20 countries across 5 continents the IBI Lorenzini group and UK distributor Bowmed Ibisqus will be well placed to meet the challenges of the future, with Tracelink on board.
Further information regarding the partnership can be found here
4th June, 2018
Ciprofloxacin IV 200mg/100ml & 400mg/200ml BAGS
Bowmed Ibisqus is delighted to announce the launch of Ciprofloxacin IV on behalf of the MA Holder Villerton Invest. This product will be distributed in strengths of 200mg/100ml and 400mg/200ml with each pack containing 5 bags.
The product has been listed with AAH and stock is available for hospital customers with or without an official contract. If you would like to discuss a pricing arrangement or stock availability for Ciprofloxacin IV or any of our other products please contact us directly on +44 (0)845 6436 703 or email us
10th April, 2018
Meropenem 500mg & 1g Vials
Bowmed Ibisqus is delighted to announce the launch of Meropenem IV on behalf of the MA Holder Villerton Invest. This product will be distributed in strengths of 500mg and 1g with each pack containing 10 vials.
The product has been listed with AAH and stock is available for hospital customers with or without an official contract. If you would like to discuss a pricing arrangement or stock availability for Meropenem IV or any of our other products please contact us directly on +44 (0)845 6436 703 or email us